Prior Art Litigation Search in Galway.

A prior art search Galway litigation counsel can build a case on has to fit an Irish system that stands apart from most of Europe — validity and infringement are heard together by one court, and Ireland is not yet inside the Unified Patent Court. The country’s patents are granted by the Intellectual Property Office of Ireland (IPOI) in Kilkenny, but the disputes are fought in Dublin, before the High Court and its fast-track Commercial Court. Galway, meanwhile, is one of Europe’s leading medical-device clusters — home to Medtronic, Boston Scientific, DePuy and CÚRAM — so the patents asserted around this region read on stents, catheters, delivery systems and diagnostics. PerspireIP builds invalidity-grade searches for the accused parties challenging those patents before the Irish courts and the EPO.

Where a prior art search Galway case is actually heard

Irish patents are granted in Kilkenny, but they are litigated in Dublin. Patent infringement and revocation proceedings must be brought in the High Court, and in practice the technically demanding cases are transferred into the Commercial Court — the Commercial List of the High Court — under Order 63A of the Rules of the Superior Courts, which expressly covers proceedings under the Patents Act 1992. There is no dedicated patent court in Galway or Connacht; a Galway medical-device dispute is funnelled to the Dublin forum like every other Irish patent fight.

The Commercial Court matters because of how it runs. It is an intensively case-managed, fast-track list built to bring complex commercial disputes to trial quickly and to control cost, with a designated judge steering directions, discovery and expert evidence. That tempo changes how invalidity evidence has to be prepared. A defendant cannot spring prior art late and hope it lands; the art must be charted, dated and explained early enough to survive the Commercial Court’s timetable and its scrutiny of expert testimony.

• High Court — the court of first instance for patent revocation and infringement, hearing validity and infringement together
• Commercial Court (Commercial List) — the fast-track, case-managed division into which qualifying patent cases are transferred
• Intellectual Property Office of Ireland (IPOI), Kilkenny — grants Irish patents; a limited revocation route also exists before the Controller
• EPO Opposition Division — central attack on a European patent within nine months of grant, reaching the Irish designation

Ireland hears validity and infringement together — one court, one record

The single most important structural fact for an accused party in Ireland is that the system is not bifurcated. Unlike Germany or Poland, where a patent office decides validity and a separate court decides infringement, the Irish High Court hears both questions in the same proceedings. A defendant sued for infringement can plead invalidity as a counterclaim and seek revocation in the very case in which it is being sued, and the same judge decides whether the patent is valid and, if so, whether it is infringed.

That unified structure raises the stakes on the prior-art record. Because there is no separate validity forum to fall back on, the invalidity case has to be won in front of the trial judge, on the evidence put before the Commercial Court. In invalidity proceedings the challenge is framed by particulars of objection served with the petition — the prior art and the grounds have to be pleaded precisely and supported by expert evidence. There is no second bite at a different tribunal, so the art has to be right the first time.

For a Galway medtech defendant, that means the invalidity search is not a courtroom afterthought — it is the spine of the defence. A rigorous, well-dated prior-art file both anchors the revocation counterclaim and shapes how the infringement case is fought, because the same claim construction governs both.

Ireland is not yet in the UPC — and that changes the fight

Ireland has signed but not ratified the Unified Patent Court Agreement. Ratification would transfer patent jurisdiction from the Irish courts to an international court, which under the Irish Constitution requires a referendum — the Forty-first Amendment. A referendum was pencilled in for 1 June 2024, then deferred by the Government in April 2024 for further public debate; hopes shifted to the October 2025 presidential election, but the September 2025 competitiveness action plan made no commitment to a date. As of 2026 there is no confirmed referendum date.

The practical consequence is decisive: there is no Irish UPC division, and the unitary patent has no effect in Ireland. The UPC Court of Appeal has confirmed that Ireland sits outside its jurisdiction. A European patent takes effect in Ireland as a national Irish patent and is enforced — and challenged — before the Irish High Court under Irish law, on its own timetable. A single pan-European UPC judgment does not reach Ireland.

For litigation counsel that is a live strategic difference. A patentee cannot use a UPC central action to knock out an Irish medical-device defendant, and an accused party has to fight the Irish designation on Irish soil. The invalidity search we build is therefore sized to the national fight in Dublin — and, where the grant is recent, to a parallel EPO opposition that can still reach the Irish designation centrally.

Irish full-term patents versus the 10-year short-term patent

Two very different Irish rights can land on a Galway product, and they demand different search strategies. The full-term patent runs up to 20 years and is granted after substantive examination for novelty and inventive step. The short-term patent runs a maximum of 10 years from filing, is limited to five claims, and — crucially — is not substantively examined against the prior art before grant.

That unexamined short-term right is a recurring feature of Irish disputes and a distinct opportunity for a defendant. Because no examiner tested it against the state of the art, a short-term patent can issue over disclosures that would have sunk it in a full examination. It is asserted against alleged infringers all the same, but its validity is often thin, and a targeted prior-art search can expose the novelty or inventive-step gap that was never scrutinised. The inventive-step threshold for a short-term patent also differs from a full patent, which shapes how obviousness combinations are argued.

• Full-term patent — up to 20 years, examined for novelty and inventive step; invalidity turns on art the examiner missed or under-weighted
• Short-term patent — up to 10 years, maximum five claims, no substantive examination; frequently vulnerable to well-dated prior art never before the Office
• Priority dating — each claim is searched against the date that actually governs it, not the cover filing date

Validating a European patent in Ireland: English, no translation

Ireland is a party to the London Agreement and English is an official language, so a granted European patent takes effect in Ireland with no translation and no validation fee — the English-language grant is automatically in force. That removes the translation-deadline pressure point that exists in countries such as Poland or Spain, where a late or deficient translation can void a European patent entirely.

For an accused party, the flip side is that you cannot expect an Irish assertion to collapse on a translation technicality. The European patent is here, in English, enforceable in the High Court from the moment of grant. The only durable route to defeat it in Ireland is on the merits — novelty and inventive step — which is exactly what a purpose-built prior-art search delivers. Because the specification is already in English, the same reference set feeds an Irish revocation counterclaim and an EPO opposition without a translation layer in between.

Where the nine-month opposition window is still open, that central EPO attack can revoke the patent in every designated state at once, Ireland included, and the same charted prior art anchors it. Once the window closes, the Irish High Court revocation route is how you reach the Irish designation.

Galway’s medical-device and diagnostics cluster: what the patents read on

Galway is one of Europe’s densest medical-technology clusters. Medtronic and Boston Scientific anchor the region with large cardiovascular campuses, joined by DePuy Synnes (Johnson & Johnson), Creganna / TE Connectivity, Aerogen and a deep base of device SMEs, while University of Galway and the Science Foundation Ireland centre CÚRAM feed the pipeline. The region sits inside an Irish medtech sector that exports on the order of €20 billion a year; Ireland manufactures a large share of the world’s coronary stents. Where there is that much device R&D, there is a dense wall of patents — and dense patents draw litigation.

The assertions that come out of this cluster are heavily cardiovascular and interventional, and each sub-field hides its decisive prior art in a different place. A stent-design claim, a catheter-steering mechanism and a diagnostic assay each call for a different search.

• Vascular and structural-heart devices — stents, stent-grafts, heart valves and delivery systems; validity fights over strut geometry, coatings and deployment mechanisms
• Catheters and delivery systems — steerable catheters, guidewires and balloon technology, where earlier device disclosures and datasheets decide the case
• Diagnostics and in-vitro devices — assays, biosensors and point-of-care platforms, where journal literature and trial data dominate
• Orthopaedics and neuromodulation — implants and stimulation devices developed across the wider cluster

Where the decisive prior art lives — and how PerspireIP builds the search

For a medical-device or diagnostic claim, the reference that kills it is rarely a headline patent. It is often a regulatory summary, a clinical-trial record or a conference paper the examiner never saw — and proving exactly when it became public is half the battle. We search patents and non-patent literature in parallel and treat the public-availability date of every reference as evidence to be established, because a disclosure is only prior art if it can be shown to predate the priority date.

• Regulatory records — FDA 510(k) summaries and PMA documents, EU/notified-body and MDR technical records that describe a device before the patent’s priority date
• Clinical evidence — ClinicalTrials.gov and other trial registries, journal literature and conference abstracts (including IEEE EMBS and cardiovascular meetings)
• Standards and product data — ISO 13485, ISO 10993 biocompatibility, ASTM and device standards, datasheets and product instructions-for-use (IFUs)
• Dating evidence — web-archive captures, library accession records and regulatory clearance dates used to fix public availability to the day

Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the priority date that governs each one, and search against that date rather than the filing date on the cover. We scope the work to the real forum — a High Court revocation counterclaim in the Commercial Court, the nine-month EPO opposition window, or support for the infringement defence — and we build claim charts an Irish judge, a technical expert or an EPO Opposition Division can follow.

We work alongside your Irish and European counsel as a specialist search partner, deliver to court and EPO deadlines, and keep every engagement confidential. Whether you are a device maker facing an assertion, a diagnostics company clearing a launch, or litigation counsel preparing a Commercial Court defence, we scale to fit — a single search, a multi-patent campaign or ongoing support. Send us the patent number and your key dates, and we will scope a prior art search Galway project within one business day.

IP Landscape & Resources in Galway

Key intellectual-property authorities and venues relevant to Galway:

• Intellectual Property Office of Ireland (IPOI) — the Irish patent office, based in Kilkenny; grants Irish full-term and short-term patents and maintains the register
• Courts Service of Ireland – Commercial Court — the High Court and its fast-track Commercial List, where patent revocation and infringement are heard together under case management
• Unified Patent Court (UPC) — the pan-European patent court; note that Ireland has signed but not ratified the UPC Agreement, so there is no Irish UPC division and the unitary patent does not take effect in Ireland
• European Patent Office (EPO) — grants European patents and runs post-grant opposition, a central attack filed within nine months of grant that reaches the Irish designation

Request a Prior Art Search in Galway

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions